FDA comment period closes on plan to bar bulk compounding of semaglutide, tirzepatide and liraglutide

The public comment window on the FDA's proposal to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list closed at 11:59 p.m. Eastern on July 30, 2026 ^[1][5]. The agency is now reviewing the comments it received and has not announced a date for a final decision ^[5].

What the proposal covers

Federal law recognizes two kinds of compounding. A 503A pharmacy is state-licensed and mixes a medication for one patient with one prescription. A 503B outsourcing facility makes large batches without patient-specific prescriptions and ships them out at scale ^[3][4]. That large-batch model is what made many telehealth subscriptions for compounded GLP-1 drugs possible ^[3].

The FDA's proposal would keep semaglutide, tirzepatide and liraglutide off the list of bulk substances that 503B facilities may use ^[1][3][5]. The FDA published the proposal in the Federal Register on May 1, 2026, and published the extension of the comment period on June 26, 2026 ^[1]. Industry groups asked for 60 additional days; the agency granted 30 ^[3]. Accounts differ slightly on the original deadline, described as June 29 in one account ^[4] and June 30 in another ^[3]. One source gives the proposal date as April 30, 2026, rather than May 1 ^[4].

Enforcement has been building for months

Before the proposal, the FDA sent roughly 80 warning letters to telehealth companies over compounded GLP-1 marketing in September 2025, about 30 more in March 2026, and another 25 during the week of June 15, 2026 ^[3]. One account describes the March 2026 action as more than 50 warning letters and the largest such wave in the history of GLP-1 compounding ^[4]. In April 2026, the agency clarified that compounders cannot sell what amounts to a copy of a commercially available drug in the same or similar strength ^[3][4].

Safety reports on compounded versions

Reported counts of adverse events tied to compounded semaglutide differ by source and date. One account cites more than 455 reports for compounded semaglutide and more than 320 for compounded tirzepatide as of early 2025 ^[3]. Another cites 520 reports for compounded semaglutide as of April 30, 2025 ^[4]. Dosing errors, including drawing the wrong amount from a multidose vial, are among the most frequently reported problems; one account describes patients administering 5 to 20 times their intended dose because of confusion between units and milligrams per milliliter ^[4]. Compounded drugs are not reviewed by the FDA for safety or effectiveness before they are sold ^[3].

The 503A pathway would remain

The proposal addresses 503B bulk production only. It does not eliminate compounding by 503A state-licensed pharmacies, which can still prepare semaglutide for an individual patient with a documented clinical need, such as an allergy to an inactive ingredient or a need for a dosage form or strength that is not commercially available. Cost alone is not a recognized basis for 503A compounding ^[4].

Separately, a review on microdosing

A narrative review titled "Multisystem Benefits of GLP-1 Microdosing" was published in Cureus in July 2026 ^[2]. It is a narrative review, a type of article that summarizes existing literature, not a clinical trial testing whether microdosing works ^[2].

Why it matters for patients

Nothing changes on July 31. The rule is not final, so compounded semaglutide remains legal to purchase, and the FDA has not said when it will decide ^[3][5]. What is narrowing is the runway for planning. If the exclusion is finalized, 503B facilities would have to stop producing these three drugs in bulk, and patient-specific 503A compounding would remain the legal route ^[3][4].

Cost is the reason most people ended up on compounded versions. Compounded semaglutide has typically cost patients $150 to $400 a month, compared with $935 to $1,349 a month for brand-name Ozempic or Wegovy without insurance, according to one compounding pharmacy's account ^[4]. Switching from a compounded vial to an FDA-approved product is a clinical decision, and doses do not always map one-to-one ^[3]. Whether a particular patient can move to an FDA-approved product depends on coverage and a prescriber's judgment, and no blanket guidance has been issued.

What happens next

The FDA has not published a date for finalizing or withdrawing the proposal ^[5]. One compounding pharmacy cited industry analysts who expect a final rule in the third quarter of 2026, but that is an expectation, not an FDA statement ^[4].